Boston Scientific (NYSE:BSX) said it completed a 10-patient, 1st-in-human trial of its IntellaTip MiFi XP ablation catheter, hoping the device will kick off a line of ablation catheters it plans to release in coming years.
The Natick, Mass.-based medical device company said the IntellaTip MiFi XP includes microsensors at its tip to provide more information during ablation procedures for type 1 atrial flutter.
Boston Scientific said it’s focusing on the $2.5 billion electrophysiology market as a "key growth area."
"We believe the design of the IntellaTip MiFi technology will redefine the quality of critical electrical information that electrophysiologists depend on during ablation procedures," said Pete Sommerness, general manager of electrophysiology, in prepared remarks. “This technology demonstrates our commitment to providing electrophysiologists with innovative solutions to help improve the health of patients around the world.”
